ArticleAdvances in therapy2025

First-Line Tislelizumab Plus Chemotherapy for Advanced Gastric Cancer with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-305.

Markus Moehler et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.